The desire to limit blood use in oncologic surgery originated with the finding of increased immunosuppression in patients who received transfusions while undergoing a renal transplant.1 Subsequently, an association was demonstrated between transfusion and increased rates of cancer recurrence and worse overall oncologic prognosis,2 with the results being most pronounced for transabdominal oncologic procedures.3,4
Odell DD, Bilimoria KY. Evaluating Appropriate Blood Transfusion in Cancer Surgery. JAMA Surg. 2016;151(6):525–526. doi:10.1001/jamasurg.2015.5104
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.